Relay Therapeutics (RLAY)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small mole...
- Open
- 19.950
- High
- 20.120
- Low
- 19.190
- Prev. Close
- 20.570
- Volume
- 2.94M
- Turnover
- 57.32M
- Avg Price
- 19.517
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 4.52%
- 52wk High
- 21.270
- Volume Ratio
- 1.41
- Turnover Ratio
- 2.06%
Relay Therapeutics Analyst Rating
View moreForecast & Rating
Aug 20, 2026Price forecast
$27.0839.14%
Forecast & RatingStrong buy
14analysts
- Strong buy78.57%
- Buy21.43%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 20 hours ago
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% - Should You Sell?
- Market Beat · 2 days ago, 04:37 AM
Spruce Street Capital LP Purchases Shares of 2,984,125 Relay Therapeutics, Inc. $RLAY
- Market Beat · Aug 21 at 07:28 AM
What is HC Wainwright's Estimate for RLAY FY2027 Earnings?
- Market Beat · Aug 20 at 02:22 AM
Relay Therapeutics, Inc. $RLAY Shares Bought by Bank of America Corp DE
- PUBT · Aug 18 at 03:17 PM
Relay Therapeutics CFO Thomas Catinazzo disposes of 17,717 common shares worth $349,703.58
- Market Beat · Aug 17 at 03:40 PM
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High Following Analyst Upgrade
